Cybin (HELP) Income towards Parent Company (2020 - 2022)

Cybin (HELP) posted Income towards Parent Company of $4.6 million for Q2 2022, up 186.82% on a QoQ basis from -$5.2 million in Q1 2021.

Cybin (HELP) Income towards Parent Company (2020 - 2022) Analysis & Trends

Cybin's Income towards Parent Company history runs 3 years deep, the most recent figure standing at $4.6 million for Q2 2022.

Quarterly Income towards Parent Company changed N/A year-over-year to $4.6 million in Q2 2022, while the trailing twelve-month figure through Mar 2026 was -$0.0 (changed 0.0% YoY) and the FY2026 annual result came in at -$147.8 million, down 74.01% from the prior year.
Income towards Parent Company was $4.6 million for Q2 2022 at Cybin, up from -$5.2 million in the prior quarter.
Across five years, Income towards Parent Company topped out at $144.2 million in Q2 2020 and bottomed at -$162.1 million in Q4 2020.
A 3-year average of -$3.7 million and a median of -$1921.8 in 2020 frame the typical range for Income towards Parent Company.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Cybin	262.76 Mn	262.76 Mn	-

Download Data